Harrison Singer (subwayease83)

magnetic/plasmonic oligomers, with tunable lengths were fabricated, affording a facile but an effective approach to modulate the optical properties of the chains. The scalable fabrication of well-aligned, linear colloidal polymers and oligomers opens up appealing opportunities for the development of sensors, subwavelength waveguides, optical tweezers, and enhanced solar harvesting devices.Objective Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis or petechiae. The thrombopoietin receptor agonist, eltrombopag is second-line agents used to treat chronic immune thrombocytopenia purpura in adults and children. Methods The aim of the present study was to evaluate the efficacy, safety and side effects, especially iron deficiency of eltrombopag treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia. Results The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 ± 4.5 years (1.2-18 years) at the beginning of EPAG treatment. Overall response rate was 74.3 %( n78). The mean time for Plt count ≥50×109/L was 11.6 ±8 weeks (range 1-34 weeks). The treatment was stopped in 27 patients (25.7%) on an average of 6.8±9 months (range 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for average of 4 months after cessation of EPAG in 3 patients. Conclusion Results of the current study imply that eltrombopag is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects especially iron deficiency during treatment.Correction to the Original Research article "Impact of Complex Care Management on Spending and Utilization for High-Need, High-Cost Medicaid Patients" published in the February 2020 issue of The American Journal of Managed Care.OBJECTIVES In 2012, the Ohio Department of Medicaid introduced requirements for enhanced care management to be delivered by Medicaid managed care organizations (MCOs). This study evaluated the impact of care management on reducing infant mortality in the largest Medicaid MCO in Ohio. STUDY DESIGN Observational study using infant and maternal individual-level enrollment and claims data (2009-2015), which used a quasi-experimental research design built on a sibling-comparison approach that controls for within-family confounders. METHODS Using individual-level data from the largest MCO in Ohio, we estimated linear probability models to examine the effect of infant engagement in care management on infant mortality. We used a within-family fixed-effects research design to determine if care management reduced infant mortality and estimated models separately for healthy infants and nonhealthy infants. RESULTS Infant engagement in care management was associated with a reduction of 7.4 percentage points (95% CI, -10.7 to -4.1; P less then .001) in infant mortality among the most vulnerable infants, those identified as not well at birth. This effect was larger in recent years and likely driven by new statewide enhanced care management requirements. Infant mortality was unchanged for healthy infants engaged in care management (coefficient = 0.03; 95% CI, -0.01 to 0.08). CONCLUSIONS This study provides evidence that care management can be effective in reducing infant mortality among Medicaid MCO enrollees, a population at high risk of mortality. Few infants were engaged in care management, suggesting to policy makers that there is room for many additional infants to benefit from this intervention.OBJECTIVES Analyses of emergency department (ED) use require visit classification algorithms based on administrative data. Our objectives were to pre